Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Japan.
HPB (Oxford). 2005;7(4):259-62. doi: 10.1080/13651820500373010.
Of 400 patients with hilar cholangiocarcinoma who were treated at Nagoya University Hospital from 1977 to 2004, 301 (75%) underwent surgical resection. Most patients underwent major hepatectomy with extrahepatic bile duct resection. The overall mortality rate was 7.6% but had decreased to 2.5% in the last 5 years (p=0.007). The overall survival rates at 5, 10 and 15 years were 22%, 13% and 10%, respectively. The survival rates of 233 patients undergoing R0 resection were 27%, 16% and 13%, respectively. R1 or R2 resection, lymph node metastasis and portal vein involvement were significant negative prognostic factors, although survival was better than in patients with unresected tumours. The results show that aggressive surgical treatment of hilar cholangiocarcinoma offers good outcomes with an acceptable mortality rate.
在名古屋大学医院，1977 年至 2004 年间共收治了 400 名肝门部胆管癌患者，其中 301 名（75%）接受了手术切除。大多数患者接受了肝外胆管切除的大范围肝切除术。总的死亡率为 7.6%，但在过去 5 年中已降至 2.5%（p=0.007）。5、10 和 15 年的总生存率分别为 22%、13%和 10%。233 名接受 R0 切除的患者的生存率分别为 27%、16%和 13%。R1 或 R2 切除、淋巴结转移和门静脉侵犯是显著的预后不良因素，尽管生存率好于未切除肿瘤的患者。结果表明，积极的肝门部胆管癌手术治疗可获得良好的效果，且死亡率可接受。
